Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories


November 19, 2009
Accelerated Aging of Blood Vessels Linked With Low CD4s
People with low CD4 cells might be more likely to have signs of accelerated aging of their blood vessels, according to a study published in the December 1 issue of Clinical Infectious Diseases.
November 18, 2009
Hep C Therapeutic Vaccine Shows Hints of Efficacy
A hepatitis C virus (HCV) therapeutic vaccine—designed to boost immune control of the virus in people already infected with HCV—has demonstrated that such an approach might work, according to a study presented at the American Association for the Study of Liver Disease (AASLD) Conference in Boston, and reported by aidsmap.
November 17, 2009
Early Treatment, Non-AIDS Disease Management Stressed in New European Guidelines
Antiretroviral (ARV) therapy is now recommended for certain people living with HIV with CD4 counts between 350 and 500 cells, according to new HIV treatment guidelines released this week by the European AIDS Clinical Society (EACS). The revised recommendations, which hint at similar changes to U.S. HIV treatment guidelines expected this winter, also review the screening, prevention and management of many non-AIDS-related diseases that are more likely to be documented in people living with HIV.
November 16, 2009
Low Vitamin D Levels in Alpine HIV Study
A new study adds to the evidence that vitamin D deficiency is common in people living with HIV. The new data, from an Italian study reported last week at the 12th European AIDS Conference in Cologne, Germany, and summarized by the National AIDS Treatment Advocacy Project (NATAP), underscore the potential importance of testing for and treating low vitamin D levels to thwart the increased risk of bone deterioration and immune system dysfunction in those infected with the virus.
CDC: Sexually Transmitted Infections Remain High in U.S.
Rates of chlamydia, gonorrhea and syphilis remain at high levels in the United States—particularly among teens—according to new data from the Centers for Disease Control and Prevention (CDC), reported on by Reuters. All three of these sexually transmitted infections (STIs) increase the risk of HIV transmission. 
November 13, 2009
HPV Therapeutic Vaccine Works in an Early Trial
A therapeutic vaccine designed to help the immune system better control human papillomavirus (HPV) was nearly 50 percent effective in eliminating precancerous genital lesions, according to a study published November 5 in The New England Journal of Medicine. These encouraging data raise hopes for treating other HPV-related cancers, notably of the cervix and anus. 
November 12, 2009
Higher Viral Loads Associated With Metabolic Syndrome
People with higher HIV levels are more likely to have a cluster of symptoms—called metabolic syndrome—associated with cardiovascular disease than people with lower viral loads, according to a study published in the December issue of the Journal of Acquired Immune Deficiency Syndromes.
November 11, 2009
New Retrovir Dosing for Kids
Dosing for the antiretroviral drug Retrovir (zidovudine) for children has been expanded and revised, according to the U.S. Food and Drug Administration (FDA). Whereas the drug had formally been recommended for children six weeks and older, it can now be used in newborns who are only 4 weeks old.
November 10, 2009
Map of Viral Loads in San Francisco Highlights HIV Treatment Inequities
New research has allowed San Francisco’s health department to map out where HIV/AIDS care should be targeted, The New York Times reports. The map uses data from individuals’ viral loads to identify these treatment gaps and show where the virus is circulating.
Topical Treatment Works Well for Anal Lesions
Trichloroacetic acid (TCA), a topical liquid sometimes used to treat genital warts, may also be useful as a therapy for anal intraepithelial neoplasia (AIN) in HIV-positive and HIV-negative people, according to a study published in the December issue of the Journal of Acquired Immune Deficiency Syndromes.
November 09, 2009
Crystal Meth Accelerates HIV Reproduction
Crystal methamphetamine (crystal meth) speeds up HIV replication in both test tube studies and in specially bred HIV-infected mice, according to a study published in AIDS Research and Human Retroviruses
November 06, 2009
Rochester Researchers Explore Possible HIV-Associated Hearing Loss
Specialists in HIV and in hearing at the University of Rochester Medical Center in New York State and are gearing up to conduct what they believe is the first large study to examine potential connections between HIV infection and hearing loss. The study, announced in a November 5 press release, is being supported by a $1.9 million grant from the National Institute on Deafness and Other Communication Disorders.
November 05, 2009
No Heart Rhythm Problem With 25 mg of Rilpivirine
People taking a 25 mg once-daily dose of rilpivirine (TMC278) had no signs of trouble with their heart rhythm, according to a study presented November 1 at the Infectious Disease Society of America conference in Philadelphia and reported by the National AIDS Treatment Advocacy Project (NATAP). These study results are encouraging, as this is the dose being explored for use in people starting HIV treatment for the first time. 
November 04, 2009
Many HIV-Positive Swiss MSM Have Chlamydia—and Don’t Know It
More than 10 percent of Swiss HIV-positive men who have sex with men (MSM) were infected with rectal Chlamydia trachomatis—many without knowing it—according to a study published November 15 in Clinical Infectious Diseases and reported by aidsmap.com.
November 03, 2009
GSK and Pfizer Launch HIV-Specific Drug Company
GlaxoSmithKline and Pfizer announced November 3 the launch of ViiV Healthcare, a collaboration between both pharmaceutical companies’ HIV drug divisions. The new company, based in London and the United States, aims to address needs specific to those living with HIV worldwide through investing in innovative research and by offering improved patient access to treatment. 
November 02, 2009
Coffee Lowers Risk of Hep C Progression
People with hepatitis C virus (HCV) who drank three or more cups of coffee per day had a 53 percent lower risk of liver disease progression than those who didn’t drink coffee, according to a study published in the November issue of Hepatology and reported by ScienceDaily. The people in the study were infected only with HCV and not with both HIV and HCV.
Most Popular Stories
HIV Eradication: One Step Closer
Life Expectancy With HIV Increases Dramatically
Mouth Full of Problems: A Crisis in HIV Dental Care
New Technology Finds Meds That Might Flush Out Hidden HIV Reservoirs
New Hope for HIV Eradication
Personalized Therapeutic Vaccine Shows Promise
Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
 
Archive

November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
My Cool Tools
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
Conference Coverage

CROI 2009
Montréal, Canada
February 8-11, 2009


48th Annual ICAAC/IDSA 46th Annual Meeting
Washington, DC
October 25-28, 2008


XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008


more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2009 Smart + Strong. All Rights Reserved. Terms of use and Your privacy